Her research is focused on the epidemiology of multiple sclerosis and neuromyelitis optica spectrum disorder (NMOSD). She has a particular interest in the roles of gender, ethnicity, migration, and vitamin D in these conditions. She has performed foundational work to validate No Evidence of Disease Activity (NEDA) as an early treatment goal on MS therapy. She is the Principal Investigator for CANOPTICS, the first Canadian national prospective study to investigate adults with NMOSD, MOG Antibody Disease, and other atypical demyelinating conditions.